Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

DragonAlgo Feb. 27 at 12:09 PM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-02-27 | Strike: $245.00 | Type: CALL Option Plan (premium): Entry: $0.54 Stop: $0.39 TP1: $0.70 TP2: $0.92 TP3: $1.30 Volatility regime is active. 🔗 https://dragonalgo.com

0 · Reply

Mmoney2424 Feb. 27 at 4:42 AM

$NVAX squeezing 🚨 watch Watch: Break and close above recent high 12.50–$13 Volume spike over current 20–25M range If that happens, shorts trapped above $15–$20 could panic $AZN $LLY $JNJ $PFE

0 · Reply

KingTrades09 Feb. 27 at 1:20 AM

$JNJ let’s get this down to 235 tomorrow or early next week

1 · Reply

IGotYouRides Feb. 26 at 8:19 PM

$NVAX $MRNA $LLY $JNJ $PFE Looks extremely undervalued I wouldn't wait to grabs shares won't be this low for long! Partnership with Pfizer........ They have a Gold standard Vaccine

0 · Reply

StockNews_Live Feb. 26 at 7:30 PM

$JNJ Johnson & Johnson announced preliminary results from a Phase 1b study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific T-cell engaging antibody, in combination with docetaxel in patie…

0 · Reply

SparkyReturns Feb. 26 at 6:46 PM

$ICU Once adult AKI is approved next year, if they get on average $20,000 per treatment for these 210,000 adult patients, that's over $4 Billion revenue annually. MC is under 10M right now. Oh, and what if they only penetrate 1% of the adult AKI market in the first year? Its still $40 Million in revenue, for a FMV around $150 M - $200 M. Share price is going to 10x within 12-18 months, IMO. $ABT $BSX $JNJ $GEHC

1 · Reply

TheHumanAlgo Feb. 26 at 6:37 PM

$JNJ Painfully slow...

0 · Reply

DragonAlgo Feb. 26 at 5:28 PM

🐉 $JNJ PUT — DragonAlgo® Signal Contract: JNJ PUT Expiry: 2026-03-20 | Strike: $250.00 | Type: PUT Option Plan (premium): Entry: $8.73 Stop: $6.28 TP1: $11.34 TP2: $14.83 TP3: $20.94 🔗 https://dragonalgo.com

0 · Reply

JaeBTrading Feb. 26 at 3:59 PM

$JNJ just waitng on the dip to 241.50-240

0 · Reply

Sunny3999 Feb. 26 at 3:57 PM

$PMN $21+ bet today doubling every month $PFE $JNJ $GILD $MRK

0 · Reply

2 Dividend Kings That Could Easily Keep The Growth Streak Alive

AWR DOV GPC PG

Feb 26, 2026, 2:30 PM EST - 18 hours ago

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Feb 24, 2026, 4:03 PM EST - 2 days ago

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Feb 23, 2026, 11:35 AM EST - 3 days ago

Does JNJ Stock Still Offer Value?

Feb 23, 2026, 10:43 AM EST - 3 days ago

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Feb 23, 2026, 10:28 AM EST - 3 days ago

Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA

Feb 21, 2026, 8:00 AM EST - 6 days ago

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

Feb 19, 2026, 5:30 PM EST - 7 days ago

Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)

Feb 19, 2026, 5:00 PM EST - 7 days ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Feb 19, 2026, 2:34 PM EST - 7 days ago

Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports

Feb 19, 2026, 2:11 PM EST - 7 days ago

Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility

Feb 19, 2026, 9:15 AM EST - 7 days ago

2 High-Yield CEFs To Enhance Your Retirement Income

AMLP ASGI BIZD BTI MO SCHD T

Feb 18, 2026, 10:44 AM EST - 8 days ago

Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory

Feb 18, 2026, 10:17 AM EST - 8 days ago

J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push

Feb 18, 2026, 10:15 AM EST - 8 days ago

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

Feb 18, 2026, 7:30 AM EST - 9 days ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

Feb 17, 2026, 8:00 AM EST - 10 days ago

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Feb 17, 2026, 6:23 AM EST - 10 days ago

Dividend Income: Lanny's December 2025 Summary

ADM AFL EMR GWW IBM LYB MCD

Feb 13, 2026, 4:19 PM EST - 13 days ago

Johnson & Johnson found liable for cancer in latest talc trial, ordered to pay $250K

Feb 13, 2026, 4:18 PM EST - 13 days ago

Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial

Feb 13, 2026, 2:43 PM EST - 13 days ago

Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial

Feb 13, 2026, 7:00 AM EST - 14 days ago

After A 55% Surge, Is JNJ Stock Still A Buy?

Feb 11, 2026, 2:23 PM EST - 15 days ago

NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review

Feb 9, 2026, 4:16 PM EST - 17 days ago

Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference

Feb 6, 2026, 7:00 PM EST - 20 days ago

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

Feb 5, 2026, 1:00 PM EST - 21 days ago

The Big 3: JNJ, XOM, KO

XOM KO

Feb 4, 2026, 1:37 PM EST - 22 days ago

These hot S&P 500 stocks show where investors are heading as they run away from tech

FDX NOC NSC RTX WMT XOM

Feb 3, 2026, 8:47 AM EST - 23 days ago

What's Behind The 50% Surge In JNJ Stock?

Feb 3, 2026, 3:00 AM EST - 24 days ago

Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia in United Kingdom and Ireland

Feb 2, 2026, 4:34 PM EST - 24 days ago

Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 1, 2026, 10:35 AM EST - 25 days ago

Ariel Focus Fund Q4 2025 Portfolio Review

ADT AMG B FISV MOS ORCL

Jan 30, 2026, 2:43 PM EST - 27 days ago

Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over

Jan 30, 2026, 7:19 AM EST - 4 weeks ago

Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations

Jan 29, 2026, 6:32 PM EST - 4 weeks ago

US judge tosses lawsuit accusing J&J of fraud over talc bankruptcy strategy

Jan 29, 2026, 12:42 PM EST - 4 weeks ago

This Winning Fund Pro Likes J&J, Lowe's, and Utility Stocks

LOW

Jan 28, 2026, 9:38 AM EST - 4 weeks ago

Johnson & Johnson: Strong Momentum Heading Into 2026

Jan 27, 2026, 3:49 PM EST - 4 weeks ago

DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

Jan 27, 2026, 8:00 AM EST - 4 weeks ago

Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile

Jan 25, 2026, 10:11 PM EST - 4 weeks ago

Best Dividend Kings: January 2026

ABBV ABM ABT ADM ADP AWR BDX

Jan 22, 2026, 12:15 AM EST - 5 weeks ago

Johnson & Johnson is doing 'great things for patients,' CFO says

Jan 21, 2026, 11:20 PM EST - 5 weeks ago

Plaintiffs' Evidence Will Be Heard in Cases Alleging J&J's Talc Products Caused Women's Ovarian Cancer, Announced Levin Papantonio Attorney Chris Tisi

Jan 21, 2026, 6:45 PM EST - 5 weeks ago

Johnson & Johnson Says Product Launches, Regulatory Approvals Drive Growth

Jan 21, 2026, 1:56 PM EST - 5 weeks ago

Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript

Jan 21, 2026, 12:15 PM EST - 5 weeks ago

Nasdaq Edges Lower; Johnson & Johnson Earnings Top Estimates

Jan 21, 2026, 10:00 AM EST - 5 weeks ago

OKLO Upgrade Rally, ULTA Adds Bullish Momentum, JNJ Earnings

OKLO ULTA

Jan 21, 2026, 7:26 AM EST - 5 weeks ago

J&J expects to hit $100 billion in revenue next year after new strategy pays off

Jan 21, 2026, 6:23 AM EST - 5 weeks ago

Johnson & Johnson forecasts 2026 profit above Wall Street estimates

Jan 21, 2026, 6:20 AM EST - 5 weeks ago

J&J's Sales and Profit Rise on Strong Cancer and Autoimmune Drug Sales

Jan 21, 2026, 6:20 AM EST - 5 weeks ago

Johnson & Johnson reports Q4 and Full-Year 2025 results

Jan 21, 2026, 1:07 AM EST - 5 weeks ago

Johnson & Johnson Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

DragonAlgo Feb. 27 at 12:09 PM

0 · Reply

Mmoney2424 Feb. 27 at 4:42 AM

0 · Reply

KingTrades09 Feb. 27 at 1:20 AM

$JNJ let’s get this down to 235 tomorrow or early next week

1 · Reply

IGotYouRides Feb. 26 at 8:19 PM

$NVAX $MRNA $LLY $JNJ $PFE Looks extremely undervalued I wouldn't wait to grabs shares won't be this low for long! Partnership with Pfizer........ They have a Gold standard Vaccine

0 · Reply

StockNews_Live Feb. 26 at 7:30 PM

0 · Reply

SparkyReturns Feb. 26 at 6:46 PM

1 · Reply

TheHumanAlgo Feb. 26 at 6:37 PM

$JNJ Painfully slow...

0 · Reply

DragonAlgo Feb. 26 at 5:28 PM

0 · Reply

JaeBTrading Feb. 26 at 3:59 PM

$JNJ just waitng on the dip to 241.50-240

0 · Reply

Sunny3999 Feb. 26 at 3:57 PM

$PMN $21+ bet today doubling every month $PFE $JNJ $GILD $MRK

0 · Reply

Suite510 Feb. 26 at 3:55 PM

$JNJ $KVUE $SPX $SPY fire sale continues at JNJ 🤣👋

1 · Reply

svillella Feb. 26 at 3:45 PM

$JNJ timber, no puck save this time

0 · Reply

BlarsonCock Feb. 26 at 2:26 PM

$BIB $GILD $IBRX $JNJ $LLY yes! This is the news that matters. We are clearly the new SOC.

0 · Reply

macrossluvsrobotech Feb. 26 at 2:25 PM

$IBRX HAHAHAH YES!!!!!!! = 📢 THE TAM EXPANSION IS REAL: SOC CONFIRMED 📢 Today’s #ASCOGU26 data confirms ANKTIVA as the Foundational Backbone for all high-risk bladder cancer. By proving dominance in the 1st-line (BCG-naïve) setting, $IBRX officially moves from a specialist tool to the Global Standard of Care. 🔥 THE QUANT DATA: ✅ 84% CR at 9 months (ANKTIVA+BCG) vs. 52% (BCG alone). ✅ p-value = 0.0455: Stat Sig Reached. The BLA path for 1st-line is wide open. ✅ 4x TAM Multiplier: 1st-line expansion increases the addressable patient pool by 400%. ✅ 700% Revenue Growth: FY2025 revenue hit $113M—adoption is surging before this massive label expansion. SMART MONEY TAKE: ANKTIVA is the "Base Platform" for immunotherapy. Starting with ANKTIVA+BCG is significantly more effective than BCG alone. With the 700% revenue trajectory established in a niche market, this expansion secures a multi-billion dollar peak sales profile. https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-completes-enrollment-pivotal-randomized-trial?field_nir_news_date_value[min]= $GILD $LLY $JNJ $BIB

0 · Reply

TheBurnerAccount Feb. 25 at 11:24 PM

$SPY Ok well there you go. $NVDA reported and nothing. Now what? What could possibly keep propping the market. $KO, $JNJ, and $WMT all trading at nosebleed insane levels? 😆 🤣 😂

0 · Reply

DragonAlgo Feb. 25 at 10:07 PM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-02-27 | Strike: $245.00 | Type: CALL Option Plan (premium): Entry: $1.92 Stop: $1.38 TP1: $2.50 TP2: $3.26 TP3: $4.61 🔗 https://dragonalgo.com

0 · Reply

ZennoCharts Feb. 25 at 8:23 PM

$AA $UAMY $JNJ $RIOT 39

0 · Reply

Tubular9988 Feb. 25 at 8:11 PM

$PMN stock could be at the start of a big move. phase 1b results this year, big pipeline, recent cash infusion, 2028 runway, big institutional and insider buying, good looking chart. could be a takeover target for $MRK $LLY $BIIB $JNJ

0 · Reply

jverroca Feb. 25 at 7:41 PM

$JNJ Building a Cell Therapy Plant in Pennsylvania. Could be a money maker!!!!!!

0 · Reply

maikl_211 Feb. 25 at 7:16 PM

$ORCL $XOM $JNJ $ASML $MA

0 · Reply

Sunny3999 Feb. 25 at 7:01 PM

$PMN will double and triple your investment $JNJ $LLY $PFE $REGN

0 · Reply

merlernin Feb. 25 at 6:01 PM

$IBRX $BIB $GILD $JNJ $REGN

0 · Reply

Market Cap	590.83B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	22.80
Forward PE	21.35
Profit Margin	28.46%
Debt to Equity Ratio	0.48

Volume	7,172,600
Avg Vol	8,953,742
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	46%
Beta	0.35
Analysts	Strong Sell
Price Target	$233.28